Quantitative Sensory Testing for Cortical Sensory Loss in CBS

diagnostic

Quantitative Sensory Testing (QST) for Cortical Sensory Loss in CBS

Overview

flowchart TD
    diagnostics_qst_cortical_senso["Quantitative Sensory Testing for Cortical Sensor"]
    diagnostics_qst_cortical_senso["Quantitative"]
    diagnostics_qst_cortical_senso -->|"related to"| diagnostics_qst_cortical_senso
    style diagnostics_qst_cortical_senso fill:#81c784,stroke:#333,color:#000
    diagnostics_qst_cortical_senso["Testing"]
    diagnostics_qst_cortical_senso -->|"related to"| diagnostics_qst_cortical_senso
    style diagnostics_qst_cortical_senso fill:#81c784,stroke:#333,color:#000
    diagnostics_qst_cortical_senso["standardized"]
    diagnostics_qst_cortical_senso -->|"related to"| diagnostics_qst_cortical_senso
    style diagnostics_qst_cortical_senso fill:#81c784,stroke:#333,color:#000
    diagnostics_qst_cortical_senso["psychophysical"]
    diagnostics_qst_cortical_senso -->|"related to"| diagnostics_qst_cortical_senso
    style diagnostics_qst_cortical_senso fill:#81c784,stroke:#333,color:#000
    style diagnostics_qst_cortical_senso fill:#4fc3f7,stroke:#333,color:#000

Quantitative Sensory Testing (QST) is a standardized psychophysical method for assessing sensory function in patients with corticobasal syndrome (CBS). Unlike routine clinical sensory exams, QST provides objective, quantitative measurements of sensory thresholds, enabling precise characterization of sensory deficits and differentiation from other parkinsonian disorders[“@rolfsen2019qst”].

QST is particularly valuable in CBS because it can objectively quantify cortical sensory loss — a core feature that helps distinguish CBS from progressive supranuclear palsy (PSP) and Parkinson’s disease[@klein2018qst].

Clinical Rationale

Why QST for CBS?

  1. Objective Quantification: QST converts subjective sensory experiences into measurable thresholds
  2. Cortical vs. Peripheral Differentiation: QST patterns can distinguish cortical sensory loss from peripheral neuropathy
  3. Disease-Specific Signatures: CBS shows characteristic QST patterns not seen in other movement disorders
  4. Progression Monitoring: Serial QST can track disease progression and treatment response

CBS-Specific Patterns

QST Parameter CBS Pattern PSP Pattern PD Pattern
Thermal thresholds Markedly elevated Mild elevation Normal
Mechanical detection Elevated Normal-mild Normal
Vibration sense Reduced Mild reduction Normal
Pain thresholds Variable Normal Normal

Testing Protocol

Equipment Requirements

  • Thermal testing: Thermode-based quantitative thermal tester (e.g., TSA-2001, Medoc)
  • Mechanical testing: Semmes-Weinstein monofilaments, vibrometer
  • Pain testing: Quantitative heat/cold pain device, pressure algometer
  • Standardized: Specific probe sizes, application rates, test site protocols

Standard Test Sites

  1. Dorsal hand (thenar eminence) — primary test site
  2. Dorsal foot (first metatarsal head) — for comparison
  3. Forearm — control site for distal vs. proximal patterns
  4. Face (cheek) — for hemispheric comparison

Testing Environment

  • Room temperature: 20–24°C
  • Skin temperature: 32–34°C (baseline)
  • Patient position: supine or seated, eyes closed
  • Verbal feedback required (cannot use with aphasic patients)

Thermal Testing

Warm Detection Threshold (WDT)

Protocol:

  • Baseline temperature: 32°C
  • Rate: 1°C/second
  • Stopping criterion: patient presses button at first warmth sensation
  • Trial count: 4–5 trials, calculate mean

Normal values: < 45°C CBS pattern: Markedly elevated (often > 50°C)

Cold Detection Threshold (CDT)

Protocol:

  • Baseline temperature: 32°C
  • Rate: 1°C/second cooling
  • Stopping criterion: patient reports cold sensation
  • Trial count: 4–5 trials

Normal values: > 28°C CBS pattern: Elevated (reduced sensitivity to cold)

Thermal Sensory Limen (TSL)

Tests the difference between warm and cold detection — indicates overall thermal sensory function.

Heat Pain Threshold (HPT)

  • Rate: 1°C/second
  • Stopping criterion: pain sensation
  • Normal: 43–47°C
  • CBS: Variable, often elevated

Cold Pain Threshold (CPT)

  • Rate: 1°C/second cooling
  • Stopping criterion: painful cold
  • Normal: < 10°C
  • CBS: Often absent (elevated threshold)

CBS-Specific Thermal Patterns

  1. Asymmetric findings: Contralateral to more affected hemisphere
  2. Warm > Cold impairment: Warm detection more affected than cold
  3. Proximal > Distal: Often affects more proximal sites
  4. Correlation with clinical signs: Correlates with clinical cortical sensory loss

Mechanical Detection Threshold (MDT)

Testing Method

Semmes-Weinstein Monofilaments:

  • Filament sizes: 0.07g to 300g
  • Application: perpendicular to skin, until just bending
  • Sites: hand, foot, forearm
  • Threshold: lowest filament consistently detected

Normal MDT: 0.07–0.4g (hand) CBS pattern: Elevated (often 1.0–4.0g)

Pattern Interpretation

  • Elevated MDT: Indicates large-fiber dysfunction or central processing deficit
  • Asymmetric: CBS typically shows side-to-side differences
  • Dissociation: Primary sensation intact but detection impaired — cortical pattern

Vibration Sense

Testing Protocol

Quantitative Vibrometry:

  • Device: Biothesiometer or neurothesiometer
  • Site: first metatarsal head, medial malleolus
  • Frequency: 100Hz standard
  • Method: Ascending/descending, calculate threshold

Normal values: < 15V (metatarsal), < 10V (malleolus) CBS pattern: Reduced (often 20–40V)

Clinical Significance

  • Vibration loss indicates large myelinated fiber involvement
  • CBS shows more prominent vibration loss than PSP
  • Correlates with posterior column involvement

Pain Threshold Testing

Pressure Pain Threshold

Protocol:

  • Device: Pressure algometer (e.g., Wagner Instruments)
  • Sites: thenar eminence, thenar muscle, forearm
  • Rate: gradual pressure increase
  • Stopping criterion: “first pain” sensation

Normal values: 150–300 kPa (hand) CBS pattern: Variable, often elevated

Heat Pain Threshold

See thermal testing section above — heat pain specifically tests pain pathways.

Clinical Interpretation

  • Elevated pain thresholds suggest cortical pain processing dysfunction
  • Paradoxically, some CBS patients have pain hypersensitivity
  • May correlate with neuropathic pain components

Data Interpretation

CBS-Specific Signatures

  1. Thermal asymmetry: > 2°C difference between sides suggests CBS
  2. Elevated thermal thresholds: Warm detection > 48°C is unusual and favors CBS
  3. Dissociated sensory loss: Intact primary sensation but impaired recognition (tactile agnosia pattern)
  4. Progression pattern: Thresholds increase over time with disease progression

Differential Diagnosis

Parameter CBS PSP Peripheral Neuropathy
Thermal asymmetry Marked Mild Symmetric
Primary sensation Intact Intact Impaired
Object recognition Impaired Intact Variable
Distribution Asymmetric Rare Distal/symmetric

Test Limitations

  1. Requires patient cooperation: Cannot test aphasic or cognitively impaired patients reliably
  2. Subject to patient attention: Fatigue affects results
  3. Not a biomarker: Correlates with clinical features, not pathological diagnosis
  4. Environmental sensitivity: Room temperature affects thermal thresholds

Integration with Clinical Assessment

QST should be interpreted alongside:

Research Applications

Biomarker Potential

  • Surrogate marker: Correlates with cortical tau burden
  • Progression marker: Serial QST tracks disease progression
  • Therapeutic response: May detect treatment effects

Clinical Trials

QST endpoints have been used in:

  • Disease-modifying therapy trials
  • Rehabilitation intervention studies
  • Neuroprotective agent trials

See Also

References

  1. Rolfsen et al., Quantitative sensory testing in atypical parkinsonism (2019)
  2. Klein et al., QST in corticobasal syndrome (2018)
  3. Baumann et al., Thermal threshold testing in parkinsonian disorders (2015)
  4. Timmermann et al., Tactile agnosia in atypical parkinsonism (2022)
  5. Ganos et al., QST patterns in CBS and PSP (2020)